miR-214 Promotes Aggressive Behavior in Triple-Negative Breast Cancer by Functionally Targeting the 3'-UTR of FRK

Serin Moon1, Sooeun Oh1, Dong-Min Kim1

  • 1Department of Hospital Pathology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.

Biomedicines
|May 27, 2026
PubMed

Insights

MicroRNA-214-3p (miR-214-3p) promotes aggressive breast cancer by targeting the tumor suppressor Fyn-related kinase (FRK). This miR-214-FRK axis offers potential therapeutic targets for triple-negative breast cancer (TNBC).

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Genetics

Background:

  • MicroRNAs (miRNAs) are crucial gene regulators in cancer progression.
  • The specific role of miR-214-3p in breast cancer, especially triple-negative breast cancer (TNBC), is debated.
  • Understanding miRNA functions is vital for developing targeted cancer therapies.

Purpose of the Study:

  • To investigate the functional role of miR-214-3p in breast cancer.
  • To identify and validate the regulatory target of miR-214-3p.
  • To explore the therapeutic potential of targeting miR-214-3p or its target in TNBC.

Main Methods:

  • Expression analysis of miR-214-3p in breast cancer cell lines.
  • Luciferase reporter assays to confirm miR-214-3p targeting of Fyn-related kinase (FRK) 3'-UTR.
  • Functional assays (proliferation, migration, invasion) upon miR-214-3p overexpression or FRK silencing.

Main Results:

  • miR-214-3p was significantly upregulated in TNBC cells, inversely correlating with FRK expression.
  • miR-214-3p directly targets and represses FRK.
  • Overexpression of miR-214-3p enhanced cell proliferation, migration, and invasion, effects mimicked by FRK silencing.

Conclusions:

  • A novel regulatory axis between miR-214-3p and FRK was identified in breast cancer.
  • This axis contributes to aggressive tumor phenotypes, particularly in TNBC.
  • Modulating miR-214-3p or FRK presents a promising therapeutic avenue for breast cancer treatment.